A Multicenter, Phase 2 Study Evaluating the Value of Radiotherapy in Advanced Diffuse Large B-cell Lymphoma Patients With Extranodal Involvement and Large Tumors Undergoing Immunochemotherapy for PET-CT Assessment of Complete Remission

• Status: Not yet recruiting
• Trial end date: 2026-05-15
• Target enrollment: 0
• Participant gender: All

Summary

This study is a prospective, single center, phase II clinical study involving 108 patients with primary and late stage Diffuse Large B-cell Lymphoma complicated by large masses and extranodal involvement. The study aims to evaluate the efficacy of radiotherapy targeting large masses and extranodal involvement in treatment-naïve advanced DLBCL patients with large mass lesions and/or extranodal involvement after they had initially been treated with standard immunochemotherapy and received complete remission as assessed by PET-CT.

After completing the standard immunochemotherapy, subjects will be randomly divided into the radiotherapy group or the non-radiotherapy group, and the curative effects will be evaluated every three months after the end of the treatment or after their leaving the group, so as to obtain the relevant data and data of the 2-year Progression Free Survival, survival of the subjects and Treatment-related side effects.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Tianjin Medical University Cancer Institute and Hospital
• Treatments: Cyclophosphamide; Doxorubicin; Prednisone; Rituximab; Vincristine

Criteria

Inclusion Criteria:

1. Using the World Health Organization (WHO) classification of diseases, newly diagnosed diffuse large B-cell lymphoma with large masses (tumor diameter ≥ 7.5cm) and or extranodal involvement patients diagnosed by histology

2. Age: no limit, male or female;

3. ECOG score: 0-2

4. The laboratory meets the following requirements:

4.1 The bone marrow hematopoietic function is basically normal: WBC ≥ 3.5×10^9/L, ANC ≥ 1.0×10^9/L, PLT ≥ 75 ×10^9/L, Hb ≥ 80g/L;

4.2 Liver function: AST/ALT≤2×ULN, TBILI≤2×ULN;

4.3 Renal Function : creatinine clearance rate(Ccr) ≥50ml/min

5. Non-menopausal or non-surgical sterilization female patients of childbearing age must have a serum pregnancy test within 3 days before the first medication, and the result is negative; and they must be non-lactating. Female patients of childbearing age or male patients whose partners are women of childbearing age must agree to use highly effective methods of contraception during the study and within 6 months after the last administration of the study drug;

6. Expected survival period ≥ 6 months;

7. The patient voluntarily joined the study and signed the informed consent;

Exclusion Criteria:

1. Serum pregnancy test positive or breastfeeding women;

2. Lymphoma patients with central nervous system (CNS) invasion;

3. Clinically significant heart disease, including unstable angina, acute myocardial infarction 6 months before randomization, congestive heart failure (NYHA), cardiac function class III or IV; or cardiac left ventricular ejection fraction <50%;

4. Patients with ≥2 grade neuropathy;

5. Patients with active hepatitis B (HBV), hepatitis C (HCV), and other acquired and congenital immunodeficiency diseases;

6. Patients with severe active infection who require systemic antibiotic treatment;

7. Have a history of serious neurological or psychiatric diseases, unable to participate in the trial normally, including dementia, epilepsy, severe depression and mania, etc.;

8. Drug abuse, medical, psychological or social conditions that may interfere with the subject's participation in the research or the evaluation of the research results;

9. Patients considered by the investigator to be unsuitable for enrollment;

-